GC
AXSM icon

Guggenheim Capital’s Axsome Therapeutics AXSM Stock Holding History

Guggenheim Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Sell
12,801
-3,449
-21% -$748K 0.02% 593
2026
Q1 		$2.75M Buy
16,250
+3,220
+25% +$556K 0.02% 608
2025
Q4 		$2.38M Buy
13,030
+513
+4% +$71.6K 0.02% 625
2025
Q3 		$1.52M Buy
12,517
+3,065
+32% +$345K 0.01% 779
2025
Q2 		$987K Sell
9,452
-751
-7% -$79.5K 0.01% 890
2025
Q1 		$1.19M Sell
10,203
-1,403
-12% -$160K 0.01% 819
2024
Q4 		$982K Sell
11,606
-1,766
-13% -$162K 0.01% 932
2024
Q3 		$1.2M Sell
13,372
-1,615
-11% -$141K 0.01% 1012
2024
Q2 		$1.21M Sell
14,987
-2,255
-13% -$167K 0.01% 1024
2024
Q1 		$1.38M Buy
17,242
+2,362
+16% +$198K 0.01% 1046
2023
Q4 		$1.18M Buy
+14,880
New +$995K 0.01% 1068

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Guggenheim Capital's AXSM Position: Q2 2026 in Review

Guggenheim Capital reduced its Axsome Therapeutics (AXSM) stake by 21% in Q2 2026, selling an estimated $748K and leaving 12,801 shares worth $3.13M. The position accounts for 0.02% of the portfolio, ranked #593.

Guggenheim Capital first reported a position in AXSM in Q4 2023 and has held it in 11 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Guggenheim Capital held 12,801 shares of Axsome Therapeutics worth $3.13M as of Q2 2026.
  • Guggenheim Capital sold 3,449 Axsome Therapeutics shares in Q2 2026, an estimated $748K.
  • Axsome Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #593 holding.
  • Guggenheim Capital first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.